Education
About Us
Working with TipRanks
Follow Us
Tekla Life Sciences Investors of Benef Interest (HQL)
NYSE:HQL
HQL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.76 - $15.90
Previous CloseN/A
Volume101.38K
Average Volume (3M)134.04K
Market Cap
$349.50M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.75
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Nov 21, 2024Dividend Yield14.6%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume143,227
30 Day Avg. Volume134,040
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
25.05% Other Institutional Investors
70.99% Public Companies and
Individual Investors
HQL FAQ
What was Tekla Life Sciences Investors of Benef Interest’s price range in the past 12 months?
Tekla Life Sciences Investors of Benef Interest lowest stock price was $12.76 and its highest was $15.90 in the past 12 months.
What is Tekla Life Sciences Investors of Benef Interest’s market cap?
Tekla Life Sciences Investors of Benef Interest’s market cap is $349.50M.
When is Tekla Life Sciences Investors of Benef Interest’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tekla Life Sciences Investors of Benef Interest’s earnings last quarter?
Currently, no data Available
Is Tekla Life Sciences Investors of Benef Interest overvalued?
According to Wall Street analysts Tekla Life Sciences Investors of Benef Interest’s price is currently Overvalued.
Does Tekla Life Sciences Investors of Benef Interest pay dividends?
Tekla Life Sciences Investors of Benef Interest pays a Quarterly dividend of $0.5 which represents an annual dividend yield of 14.6%. See more information on Tekla Life Sciences Investors of Benef Interest dividends here
What is Tekla Life Sciences Investors of Benef Interest’s EPS estimate?
Tekla Life Sciences Investors of Benef Interest’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tekla Life Sciences Investors of Benef Interest have?
Currently, no data Available
What happened to Tekla Life Sciences Investors of Benef Interest’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tekla Life Sciences Investors of Benef Interest?
Currently, no hedge funds are holding shares in HQL
---
Company Description
Tekla Life Sciences Investors of Benef Interest
HQL is a mutual fund that focuses on investing in the life sciences industry. It is managed by Tekla Capital Management LLC and offers investors the opportunity to benefit from the growth potential of companies in the healthcare, biotechnology, and pharmaceutical sectors. With a ticker symbol of HQL, this fund provides investors with a diversified portfolio of life sciences companies, allowing them to potentially capitalize on the advancements and innovations in this rapidly evolving industry.
---
Technical Analysis
---